Prelude Therapeutics Incorporated
PRLD
$5.55
$0.193.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 220.34% | 138.86% | 73.43% | 250.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 220.34% | 138.86% | 73.43% | 250.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 220.34% | 138.86% | 73.43% | 250.00% | -- |
| SG&A Expenses | -22.94% | -21.41% | -22.33% | -20.08% | -8.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.66% | -32.26% | -21.34% | -10.06% | -0.19% |
| Operating Income | 51.04% | 40.82% | 26.09% | 15.51% | 5.11% |
| Income Before Tax | 51.34% | 39.14% | 21.76% | 15.01% | 4.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.34% | 39.14% | 21.76% | 15.01% | 4.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.34% | 39.14% | 21.76% | 15.01% | 4.26% |
| EBIT | 51.04% | 40.82% | 26.09% | 15.51% | 5.11% |
| EBITDA | 51.59% | 41.26% | 26.38% | 15.80% | 5.35% |
| EPS Basic | 55.24% | 40.50% | 22.58% | 17.09% | 9.10% |
| Normalized Basic EPS | 56.24% | 41.48% | 23.56% | 17.09% | 9.10% |
| EPS Diluted | 47.30% | 32.79% | 22.81% | 17.32% | 9.36% |
| Normalized Diluted EPS | 56.24% | 41.48% | 23.56% | 17.09% | 9.10% |
| Average Basic Shares Outstanding | 10.88% | 3.59% | 1.52% | 2.37% | 5.19% |
| Average Diluted Shares Outstanding | 10.88% | 3.59% | 1.52% | 2.37% | 5.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |